Harvard Bioscience (NASDAQ: HBIO) and Fulgent Genetic (NASDAQ:FLGT) are both small-cap computer and technology companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, valuation and earnings.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Harvard Bioscience and Fulgent Genetic, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Harvard Bioscience 0 0 2 0 3.00
Fulgent Genetic 0 0 3 0 3.00

Harvard Bioscience currently has a consensus price target of $5.75, indicating a potential upside of 79.69%. Fulgent Genetic has a consensus price target of $10.67, indicating a potential upside of 93.59%. Given Fulgent Genetic’s higher probable upside, analysts clearly believe Fulgent Genetic is more favorable than Harvard Bioscience.

Profitability

This table compares Harvard Bioscience and Fulgent Genetic’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Harvard Bioscience -4.37% 1.45% 0.99%
Fulgent Genetic -0.42% -0.02% -0.02%

Insider and Institutional Ownership

61.0% of Harvard Bioscience shares are held by institutional investors. Comparatively, 16.8% of Fulgent Genetic shares are held by institutional investors. 9.8% of Harvard Bioscience shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Harvard Bioscience and Fulgent Genetic’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Harvard Bioscience $100.79 million 1.11 $3.21 million ($0.13) -24.62
Fulgent Genetic $20.81 million 4.70 $2.17 million ($0.38) -14.50

Harvard Bioscience has higher revenue and earnings than Fulgent Genetic. Harvard Bioscience is trading at a lower price-to-earnings ratio than Fulgent Genetic, indicating that it is currently the more affordable of the two stocks.

Summary

Harvard Bioscience beats Fulgent Genetic on 7 of the 11 factors compared between the two stocks.

Harvard Bioscience Company Profile

Harvard Bioscience, Inc. is a developer, manufacturer and marketer of a range of scientific instruments, systems and lab consumables used for basic research, drug discovery, clinical and environmental testing. The Company’s products are sold to thousands of researchers in over 100 countries through its global sales organization, Websites, catalogs and through distributors. The Company’s product range is organized into three commercial product families: Cell and Animal Physiology (CAP), Lab Products and Services (LPS), and Molecular Separation and Analysis (MSA). The Company sells these products under brand names, including Harvard Apparatus, KD Scientific, Denville Scientific, AHN, Hoefer, Biochrom, BTX, Warner Instruments, MCS, HEKA, Hugo Sachs Elektronik, Panlab, Coulbourn Instruments, TBSI and CMA Microdialysis. The Company’s products consist of instruments, consumables and systems that are made up of various individual products.

Fulgent Genetic Company Profile

Fulgent Genetics, Inc. is a technology company. The Company offers genetic testing to provide physicians with clinically actionable diagnostic information to improve quality of patient care. The Company has developed a technology platform that integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory processes. As of December 31, 2015, the Company’s test menu includes approximately 18,000 single-gene tests and over 200 pre-established, multi-gene, disease-specific panels that collectively test for approximately 7,500 genetic conditions, including various cancers, cardiovascular diseases and neurological disorders. The Company’s gene probes are specifically engineered to generate genetic data that is optimized for its software, which enables to rapidly incorporate new genes into its test menu, develop new panels of disease-specific tests and customize tests for its customers.

Receive News & Stock Ratings for Harvard Bioscience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience Inc. and related stocks with our FREE daily email newsletter.